| Literature DB >> 33437514 |
Shing Yi Pan1,2,3, Yvonne Cashinn Chia2,3, Hui Rong Yee2,3, Angelina Ying Fang Cheng2,3, Clarice Evey Anjum2,3, Yenny Kenisi2,3, Mike Ks Chan1,2,3, Michelle Bf Wong1,2,3.
Abstract
The immune system is a complex network of specialized cells and organs that recognises and reacts against foreign pathogens while remaining unresponsive to host tissues. This ability to self-tolerate is known as immunological tolerance. Autoimmune disease occurs when the immune system fails to differentiate between self and non-self antigens and releases autoantibodies to attack our own cells. Anti-idiotypic (anti-ID) antibodies are important in maintaining a balanced idiotypic regulatory network by neutralising and inhibiting the secretion of autoantibodies. Recently, anti-ID antibodies have been advanced as an alternative form of immunotherapy as they can specifically target autoantibodies, cause less toxicity and side effects, and could provide long-lasting immunity. This review article discusses the immunomodulatory potential of anti-ID antibodies for the treatment of autoimmune diseases.Entities:
Year: 2020 PMID: 33437514 PMCID: PMC7787174 DOI: 10.2144/fsoa-2020-0142
Source DB: PubMed Journal: Future Sci OA ISSN: 2056-5623